BioAge's BGE-102 Shows Robust Brain Penetration and 98% IL-1 Suppression in Positive Phase 1 Interim Data
Strong Brain Penetration Sets BGE-102 Apart Among NLRP3 Inhibitors
BioAge Labs (NASDAQ: BIOA) has revealed encouraging interim data from its ongoing Phase 1 trial of BGE-102, an investigational, orally available NLRP3 inhibitor. BGE-102 achieved a high degree of brain penetration—a critical milestone that few drugs in this category have demonstrated—enabling it to address both central and peripheral inflammation linked to aging, cardiovascular risk, and metabolic diseases.
Positive Phase 1 Data: Tolerability and Target Engagement Exceed Expectations
Across single and multiple ascending dose (SAD and MAD) cohorts, BGE-102 was well tolerated at doses ranging from 10 mg up to 120 mg. The frequency and severity of adverse events remained mild to moderate, with no severe side effects requiring intervention.
The real standout metric was the strong suppression of interleukin-1 (IL-1), a key pro-inflammatory cytokine: BGE-102 achieved 90% suppression at the 60 mg dose and 98% at 120 mg after 14 days of treatment. Additionally, pharmacokinetic results indicated that BGE-102 maintained plasma concentrations exceeding the target inhibitory threshold (IC90) throughout a 24-hour dosing period, supporting its once-daily regimen.
| Cohort | Dose (mg) | IL-1 Suppression (%) | Brain (CSF) IC90 Exceeded | Tolerability |
|---|---|---|---|---|
| SAD | 10, 30, 60, 120 | Up to 98 | 60 and 120 | Well-tolerated |
| MAD | 60, 120 | 90–98 | Yes (at both doses) | Well-tolerated |
Study Expansion Targets Obese Patients with Elevated Inflammation
Encouraged by the drug’s pharmacodynamics and safety profile, BioAge has broadened the ongoing Phase 1 study to include obese participants with elevated high-sensitivity C-reactive protein (hsCRP), a biomarker for systemic inflammation. Data from this extension and further multiple dose cohorts are expected in the first half of 2026. These additional results may provide crucial proof-of-concept for the drug’s anti-inflammatory effects, especially as BGE-102 targets the NLRP3–IL-1 axis, a key driver of elevated CRP and metabolic disease risk.
Next Steps: Milestones on the Horizon
BioAge has mapped out the next phases of BGE-102’s clinical journey:
- First half 2026: Full Phase 1 multiple dose results in obese patients (focus on hsCRP and IL-1 changes)
- First half 2026: Launch of a Phase 2a proof-of-concept study in approximately 100 patients with obesity and cardiovascular risk factors, targeting reduction in hsCRP and other metabolic markers
- Second half 2026: Expected data readout from the Phase 2a study
Why the Brain Penetration and IL-1 Suppression Matter
BGE-102’s robust ability to reach and suppress inflammatory markers within the brain could give it a unique edge over other NLRP3 inhibitors currently in development. Many diseases of aging—including neurodegeneration, cardiovascular disease, and metabolic syndrome—are believed to be driven by central inflammation. Targeting these pathways more directly may ultimately broaden BGE-102’s clinical impact beyond the original trial scope.
Takeaway: BGE-102 Positions BioAge for Key Data and Pipeline Expansion
Investors and industry watchers may want to track further readouts and expansion in obese patients as BioAge pushes toward Phase 2 trials in 2026. The company’s pipeline also includes APJ agonists in obesity and other aging-related metabolic targets, which could draw increasing interest if BGE-102 continues to show safety and biomarker effects in line with today’s results.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI